Table IV.
Bioequivalence of artemisinin in 15 healthy Vietnamese male volunteers in a 4-sequence crossover study. Values are given as geometric mean values (90% CI).
| Parameter | T1/T2 Ratio | T3/T2 Ratio | T4/T2 Ratio |
|---|---|---|---|
| Cmax | 121% (92.5–158) | 278% (213–363) | 131% (100–171) |
| Cmax/D | 121% (92.5–158) | 89.0% (68.2–116) | 131% (100–171) |
| AUC0–last | 122% (101–148) | 315% (260–381) | 131% (109–159) |
| AUC0–last/D | 122% (101–148) | 101% (83.2–122) | 131% (109–159) |
| AUC0–∞ | 120% (98.0–146) | 313% (256–383) | 128% (105–157) |
| AUC0–∞/D | 120% (98.0–146) | 100% (82.0–123) | 128% (105–157) |
T1 = micronized artemisinin powder (160 mg); T2 = standard Vietnamese artemisinin formulation (160 mg); T3 = standard Vietnamese artemisinin formulation (500 mg); T4 = micronized artemisinin powder (160 mg) and piperaquine phosphate (720 mg) in a fixed tablet formulation; D = dose (milligram per kilogram).